Bavarian Nordic (OTCPK:BVNRY) has received FDA approval for its vaccine Vimkunya for the prevention of chikungunya. The virus-like particle, or VLP, vaccine is approved for people aged 12 and older.

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention ...

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers.On track for commercial launch in the U.S. in the ...

The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...

Guillain-Barre Syndrome (GBS) is a rare neurological disorder in which the body’s immune system mistakenly attacks the ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use ...

Valneva (VALN) stock gained as its chikungunya vaccine receives marketing authorization in the U.K., expanding the single-dose shot's global reach. Read more here.

The world’s first vaccine for mosquito-borne chikungunya virus has been approved by the UK’s Medicines and Healthcare ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 February 2025, approved the vaccine chikungunya vaccine (live) (brand name ...

At least five suspected cases of chikungunya were recorded in Davao City in January 2025. The residents who were suspected of ...

While Zika has been reported in more than 90 countries, surprisingly little is known about what exactly drives Zika ...

While much of Valneva's focus these days is centered on its landmark vaccine for chikungunya virus, the French immunization specialist's catalog of older shots continues to serve up fresh governmen | ...